Neoadjuvant tyrosine kinase inhibition in locally-advanced non-small cell lung cancer: Two cases and a brief literature review

Keyphrases

• Neoadjuvant 100%
• Stage III Non-small Cell Lung Cancer 100%
• Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) 100%
• EGFR mutation 100%
• Tyrosine Kinase Inhibition 100%
• ALK mutation 100%
• Non-small Cell Lung Cancer Patients 50%
• Targeted Therapy 50%
• Patient Outcomes 50%
• Survival Benefit 50%
• Driver mutations 50%
• EGFR Inhibitors 50%
• Durable Response 50%
• Dramatic Response 50%
• Stage III Disease 50%
• ALK Inhibitor 50%
• Metastatic Non-small Cell Lung Cancer 50%

Biochemistry, Genetics and Molecular Biology

• Receptor Tyrosine Kinase 100%
• Epidermal Growth Factor Receptor 100%
• Tyrosine Kinase 100%